Trials / Not Yet Recruiting
Not Yet RecruitingNCT05497401
A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- BonusBio Group Ltd · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The efficacy of the allogeneic cell-therapy product MesenCure in addition to standard of care will be evaluated in comparison to placebo control in 300 moderate to severe Covid patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MesenCure | Enhanced mesenchymal cell-based product |
| OTHER | Placebo | Saline |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2028-06-01
- Completion
- 2028-10-01
- First posted
- 2022-08-11
- Last updated
- 2025-08-11
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05497401. Inclusion in this directory is not an endorsement.